Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.
Opinion Statement: In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 ar...
| Publicado en: | Current Treatment Options in Oncology Vol. 20; no. 9 |
|---|---|
| Autores principales: | , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Sep2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138268707&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 138268707 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Sep2019 vid: 20 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 138268707 138268707 NLM31428952 138268707 10.1007/s11864-019-0670-1 NLM31428952 138268707 ppct: 1 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. aug: au: Sonbol, Mohamad Bassam Halfdanarson, Thorvardur R. affil: Mayo Clinic Cancer Center, Phoenix, AZ, USA sug: subj: Neuroendocrine Tumors Therapy Neuroendocrine Tumors Diagnosis Neoplasm Grading Disease Management Combined Modality Therapy Methods Clinical Trials Neuroendocrine Tumors Etiology Treatment Outcomes ab: Opinion Statement: In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|